(Q36286223)

13 August 2017

1 reference

title

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. (English)

1 reference

13 August 2017

0 references

1 reference

2

Lesley J Scott

1 reference

13 August 2017

M Asif A Siddiqui

1

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

65

1 reference

13 August 2017

issue

15

1 reference

13 August 2017

page(s)

2179-2208

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200565150-00014

13 August 2017

exact match

0 references

cites work

Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands

1 reference

12 December 2020

Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease

1 reference

12 December 2020

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

1 reference

12 December 2020

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

12 December 2020

Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

1 reference

12 December 2020

Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis

1 reference

12 December 2020

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

12 December 2020

The effect of etanercept and infliximab on the production of tumour necrosis factor α, interferon-γ and GM-CSF in in vivo activated intestinal T lymphocyte cultures

1 reference

12 December 2020

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

12 December 2020

Management for severe Crohn's disease: a lifetime cost-utility analysis.

1 reference

12 December 2020

Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis

1 reference

12 December 2020

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

12 December 2020

Long term safety of infliximab

1 reference

12 December 2020

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

1 reference

12 December 2020

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

12 December 2020

The effects of infliximab maintenance therapy on health-related quality of life.

1 reference

12 December 2020

Challenges in Crohn's disease

1 reference

12 December 2020

Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study

1 reference

12 December 2020

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

12 December 2020

Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.

1 reference

12 December 2020

Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis

1 reference

12 December 2020

Crohn's disease in Japan: diagnostic criteria and epidemiology

1 reference

12 December 2020

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1 reference

12 December 2020

Medical therapy of Crohn disease

1 reference

12 December 2020

Infliximab in active early rheumatoid arthritis

1 reference

12 December 2020

1 reference

12 December 2020

Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease

1 reference

12 December 2020

Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)

1 reference

12 December 2020

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

12 December 2020

Advances in the management of Crohn's disease: economic and clinical potential of infliximab.

1 reference

12 December 2020

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

1 reference

12 December 2020

The incidence and management of infusion reactions to infliximab: a large center experience

1 reference

12 December 2020

Emerging biologic therapies in inflammatory bowel disease.

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

1 reference

12 December 2020

Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis

1 reference

12 December 2020

Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis

1 reference

12 December 2020

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

1 reference

12 December 2020

Infliximab: in ankylosing spondylitis

1 reference

12 December 2020

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis

1 reference

12 December 2020

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

1 reference

12 December 2020

Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease

1 reference

12 December 2020

Safety of tumour necrosis factor-alpha antagonists

1 reference

12 December 2020

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.

1 reference

12 December 2020

Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial

1 reference

12 December 2020

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

12 December 2020

American Gastroenterological Association medical position statement: perianal Crohn's disease

1 reference

12 December 2020

Review article: the limitations of corticosteroid therapy in Crohn's disease

1 reference

12 December 2020

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

12 December 2020

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)

1 reference

12 December 2020

Increased levels of NF-kappaB inhibitors (IkappaBalpha and IkappaBgamma) in the intestinal mucosa of Crohn's disease patients during infliximab treatment

1 reference

12 December 2020

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

1 reference

12 December 2020

Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings.

1 reference

12 December 2020

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

1 reference

12 December 2020

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

12 December 2020

A clinical and economic review of disease-modifying antirheumatic drugs

1 reference

12 December 2020

Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis

1 reference

12 December 2020

The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

1 reference

12 December 2020

Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease

1 reference

12 December 2020

Guidelines for the management of inflammatory bowel disease in adults

1 reference

12 December 2020

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis

1 reference

12 December 2020

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

1 reference

12 December 2020

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

1 reference

12 December 2020

Infliximab induced T lymphocyte apoptosis in Crohn's disease.

1 reference

12 December 2020

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

1 reference

12 December 2020

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

12 December 2020

Inflammatory bowel disease. Part II: Crohn's disease--pathophysiology and conventional and alternative treatment options.

1 reference

12 December 2020

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

1 reference

12 December 2020

Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.

1 reference

12 December 2020

Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis

1 reference

12 December 2020

Infliximab: a review of its use in the management of rheumatoid arthritis

1 reference

12 December 2020

Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

1 reference

12 December 2020

Cost-utility of initial medical management for Crohn's disease perianal fistulae.

1 reference

12 December 2020

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

1 reference

12 December 2020

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

12 December 2020

Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy

1 reference

12 December 2020

Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease

1 reference

12 December 2020

The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study

1 reference

12 December 2020

A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease.

1 reference

12 December 2020

Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis

1 reference

12 December 2020

Management of Crohn's disease in adults

1 reference

12 December 2020

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

12 December 2020

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

1 reference

12 December 2020

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study

1 reference

12 December 2020

Biological agents for rheumatoid arthritis: targeting both physical function and structural damage

1 reference

12 December 2020

A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab

1 reference

12 December 2020

Economic implications of biological therapies for Crohn's disease: review of infliximab

1 reference

12 December 2020

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

1 reference

12 December 2020

10.2165/00003495-200565150-00014

Identifiers

DOI

1 reference

Dimensions Publication ID

13 August 2017

1015187996

0 references

1 reference